Holen Sie sich die Stockscreener-App
0.3082
1.05%
0.0024
Schlusskurs vom Vortag:
$0.3058
Offen:
$0.31
24-Stunden-Volumen:
36,982
Relative Volume:
0.02
Marktkapitalisierung:
$3.82M
Einnahmen:
$1.75M
Nettoeinkommen (Verlust:
$-5.68M
KGV:
-0.0633
EPS:
-4.8726
Netto-Cashflow:
-
1W Leistung:
+4.39%
1M Leistung:
+1.05%
6M Leistung:
-27.97%
1J Leistung:
-63.69%
1-Tages-Spanne:
$0.3082
$0.31
1-Wochen-Bereich:
$0.29
$0.3393
52-Wochen-Spanne:
$0.197
$1.79
Scisparc Ltd Stock (SPRC) Company Profile
Vergleichen Sie SPRC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
0.3082 | 3.82M | 1.75M | -5.68M | 0 | -4.8726 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.31 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.85 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.75 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
562.50 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.12 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Scisparc Ltd Aktie (SPRC) Neueste Nachrichten
SciSparc Ltd. Advances Merger with AutoMax Motors - TipRanks
SciSparc announces publication of Japanese patent application - MSN
Therapix Biosciences Ltd. Announces Executive Changes - marketscreener.com
SciSparc Unveils Japanese Patent for Novel Pain Relief Combination - TipRanks
SciSparc secures Japanese patent for pain relief combo By Investing.com - Investing.com South Africa
SciSparc Ltd. Announces Publication of Japanese Patent Application - marketscreener.com
SciSparc secures Japanese patent for pain relief combo - Investing.com
SciSparc Ltd. Announces Publication of Novel Japanese Patent for Enhanced Pain Management Therapy Combining Paracetamol and PEA - Nasdaq
SciSparc Announces Publication of Japanese Patent Application - GlobeNewswire
SciSparc's New Pain Relief Patent Could Make Paracetamol Safer for Millions - Stock Titan
SciSparc sets annual shareholder meeting for June 25 By Investing.com - Investing.com Nigeria
SciSparc sets annual shareholder meeting for June 25 - Investing.com Australia
SciSparc Ltd. Announces Annual General Meeting for June 2025 - TipRanks
SciSparc and Clearmind Secure European Patent for Cocaine Addiction Therapy - TipRanks
SciSparc Ltd. Announces European Patent Application for Cocaine Addiction Treatment in Collaboration with Clearmind Medicine Inc. - Nasdaq
SciSparc-Clearmind Collaboration Leads to Publication of - GlobeNewswire
SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction - Stock Titan
Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.0 Million Private Placement for SciSparc Ltd. (NASDAQ: SPRC) - The Globe and Mail
SciSparc Ltd: Weathering Stock Market Storms with 3.17M Market Cap - investchronicle.com
A review of SPRC’s current quarter earnings predictions - uspostnews.com
What's Going On With jeffs' Brands Today? - Benzinga
Jeffs' Brands to Sell Smart Repair Pro Unit, SciSparc Nutraceuticals Stake to Plantify Foods; Shares Jump - marketscreener.com
Jeffs' Brands Ltd Enters Agreement to Sell Smart Repair Pro and SciSparc Stake to Plantify Foods, Inc. for Equity Interest - Nasdaq
SciSparc and Clearmind file patent for eating disorder treatment - Investing.com
SciSparc and Clearmind file patent for eating disorder treatment By Investing.com - Investing.com India
SciSparc announces collaboration with Clearmind Medicine - TipRanks
SciSparc and Clearmind File Patent for Eating Disorder Treatment - TipRanks
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders - The Manila Times
SciSparc-Clearmind Collaboration Leads to Filing of - GlobeNewswire
Novel Eating Disorder Treatment Patent Filed for 70M Patient Market | SPRC Stock News - Stock Titan
3 Reasons OMI is Risky and 1 Stock to Buy Instead - The Globe and Mail
Thinking Of Selling SciSparc Ltd (NASDAQ: SPRC) Stock? Check This Out First - Stocksregister
SciSparc (NASDAQ:SPRC) Shares Down 6% – Here’s Why - Defense World
SciSparc Extends Deadline for Miza III Ventures Deal - TipRanks
SciSparc Ltd. Extends Merger Agreement with AutoMax Motors - TipRanks
SciSparc Ltd. (NASDAQ:SPRC) Short Interest Up 1,435.0% in March - Defense World
SciSparc announces resale of 61.21M shares by selling shareholders; shares down - MSN
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement - Louisiana First News
SciSparc and Clearmind Advance Cocaine Addiction Treatment with South Korean Patent Application - TipRanks
Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Is the SciSparc Ltd (NASDAQ:SPRC) stock an investment opportunity? - US Post News
SciSparc Shares Are Soaring Monday: What's Going On? - Benzinga
Scisparc, Clearmind apply for patent in South Korea for its co-developed treatment to overcome cocaine addiction - Marketscreener.com
SciSparc announces publication of patent via Clearmind collaboration - TipRanks
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea - The Manila Times
SciSparc Ltd. and Clearmind Medicine Inc. Announce Patent Application for Combination Treatment of Cocaine Addiction - Nasdaq
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea - The Manila Times
SciSparc Extends $2 Million Loan to Support Automax?s Growth Following Automax?s Entry into Direct Import of JAC Electric Vehicles - Marketscreener.com
SciSparc Ltd. Agrees to Sell MitoCareX to N2OFF - TipRanks
SciSparc signs definitive agreement to sell MitoCareX to N2OFF - TipRanks
SciSparc to sell MitoCareX to N2Off for $700,000 - MSN
Finanzdaten der Scisparc Ltd-Aktie (SPRC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.37%
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):